Gopal P. Jadhav, PhD

Gopal P. Jadhav, PhD

Gopal P. Jadhav, PhD

Assistant Professor
Board Membership, Creighton University, Health ans Safety
School of Medicine, Omaha Campus

Expertise/Specializations

  • Synthetic organic chemistry: Hands on experience in modern synthetic organic chemistry like multi-step syntheses of drug like molecules, heterocycles, peptides, etc., parallel synthesis using Radley’s. Independent planning and execution of SAR.
  • Analytical techniques: Hands on modern separations techniques. Adept at using NMR, HPLC (analytical, prep., normal, RP, ion-exchange, size-exclusion), GC-, LC-MS, UV/VIS, IR, CD, detection based on fluorescence.
  • Hands on Molecular modelling softwares: Schrodinger Maestro (GLIDE, Homology Modeling, Epik, Ligprep, Protprep) Sybyl7.3, 8.0, Pymol, Database search (Zinc) and processing, Docking (GOLD, Glide, Openeye), Homology modelling, SciFinder, Beilstein, MDL/ISIS
  • Bioassay techniques: Advanced skills in Splenocyte proliferation assays in murine leukocytes and human blood monocytes (immune assay) and Bioluminescence induction assay using luminometer (microbiological assay).

Academic Appointments

Department

  • Pharmacology and Neuroscience

Position

  • Assistant Professor

Teaching Activity

  • PHR 241- Pharmacology I
  • PHR 536 - Drugs & Drug Targets

Biography

After earning a Masters of Pharmacy from Pune University (India) in 1998, Dr. Gopal worked as a synthetic chemist for a year and taught medicinal chemistry for three years before beginning a PhD at the University of Nottingham (UK). In the five years after his Ph.D., he worked as a post-doctoral research fellow on three projects: one on cancer research, financed by the BBSRC in the UK; another on drug discovery, funded by the Wellcome Trust; and one on osteoporosis, funded by the MRC in the UK.
After that, Dr. Jadhav worked for about two years as a senior research scientist at GlaxoSmithKline's RD Alternative Discovery & Development (Madrid Trescants, Spain) on a collaborative project that involved structural optimization of the hPDE4 inhibitor GSK675728A to produce novel pharmacophore(s) as potent TbrPDE1 inhibitors that are selective over hPDEs in the management of African sleeping sickness (CNS disorder). 
Dr. Gopal started working as a postdoctoral researcher at Creighton University in June 2016 and was later promoted to assistant professor of medicinal chemistry in early 2017. He is presently tenure track faculty in the school of medicine working under Dr. Peter Abel.

Lab Research Focus: Dr. Jadhav’s Lab is aimed at;
A) Molecular docking and Structure Activity Relationship (SAR) based small molecular drug discovery to tackle biological problems such as Neuroinfllamatory disorders, Cancers, Noise induced hearing loss (NIHL) and Antibiotic resistant Bacterial infections. Current projects involve (1) Development of Triggering receptors expressed on myeloid cells-1 (TREM1) inhibitors to treat neuronal disorders, NIHL and liver cancer. (2) Development of small molecules as Mvfr inhibitors to treat antibiotic resistant Pseudomonas aeruginosa infections. 
B) PROTAC (Proteolysis targeting chimeras) therapeutics: to address liver cancer and Neuroinflmmations.
C) Dual conjugates of Latanoprost acid  to release Nitrous oxide (NO) and Hydrogen suflide (H2S) in the management of gloucoma.

Curriculum Vitae

Publications and Presentations

Articles

  • , Chapter 10, 237-250
  • , 2 (1), 1007
  • , 5 (3), 45
  • , 23 (4), 875
  • , 31
  • , 57(6), 2813-2819
  • , 42(5), 1–10
  • , 54, 3348– 3359
  • , 36(8), 505-508
  • , 36(8), 505-508
  • , 35(8), 475-480
  • , 35(11), 718-720
  • , 60(4), 246-248

Editing and Reviews

Presentations

Research and Scholarship

Research and Scholarship Interests

  • Drug discovery in Cardiac and cardiovascular disorders
    Drug discovery in immuno and inflammatory disorders
    Drug discovery in Quorum sensing
    Drug discovery in Highly neglected diseases
     

Current Research Projects

  • Dr. Jadhav is working on the design and development of novel inhibitors of triggering receptor expressed on myeloid cells–1 (TREM-1), in the management of life threatening sepsis and CVD. This interdisciplinary research warrants use of computer aided drug design approach to develop and synthesis of small drug like molecules. Current inhibitors are peptide molecules (LR-17 and LR-12), that have a very short half-life and possibly with multiple targets.

    Molecular docking and HTS assay techniques will be employed to identify from from a library of 80000 diverse chemical molecules. These hits will be tested for TREM-1 inhibitory potential to identify new chemical lead(s). Lead(s) will be recruited for extensive chemical modifications (SAR- development) in order to optimize potency, toxicity and druggability.  

Awards and Honors

  • , 2019
  • Novel Cyclic Phenoxy Compounds and Improved Treatments for Cardiac and Cardiovascular Disease, 2015
  • Novel Ether Linked Compounds and Improved Treatments for Cardiac and Cardiovascular Disease, 2012
  • PHENOXYPROPANOL DERIVATIVES AND THEIR USE IN TREATING CARDIAC AND CARDIOVASCULAR DISEASES, 2012